Breaking News on MFN ‘Targets’ … and a Review of the Right’s Reaction to the Policy
Shares:
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv
I mentioned yesterday that Merck had dropped its annual drug-price transparency report, warning that Merck’s numbers probably shouldn’t be extrapolated to the broader industry. After all, most companies don’t have